A phase III, Randomized, Open - label Study of Lopinavir/Ritonavir tablets versus soft gel capsules and once daily versus twice daily administration, when coadministered with NRTIs in antiretroviral-naive HIV - 1 infected subjects.
- Conditions
- Treatment of HIV infection in antiretroviral - naive HIV-1 infected subjects.MedDRA version: 6.1Level: PTClassification code 10020161
- Registration Number
- EUCTR2005-001430-32-IT
- Lead Sponsor
- Abbott GmBH Co KG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method